课题基金 / 基金详情

Development of a novel molecular therapy for rheumatoid arthritis by regulation of Th1/Th2 differentiation

Development of a novel molecular therapy for rheumatoid arthritis by regulation of Th1/Th2 differentiation
通过调节 Th1/Th2 分化开发治疗类风湿性关节炎的新型分子疗法
批准号:
14370167
负责人:
SHIBUYA Kazuko
金额:
$8.58万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2003

项目摘要

项目成果

SHIBUYA Kazuko的其他基金

相似基金

相关文献

中文摘要
翻译
由于Th1细胞参与了类风湿关节炎的免疫病理过程,因此需要了解Th1fTh2分化的分子机制,以开发治疗类风湿关节炎的新疗法。Th1和Th2细胞来源于CD4阳性的初始T细胞。由于CD4阳性的初始T细胞需要与抗原提呈细胞间结合才能分化为辅助性T细胞,因此我们研究了CD4阳性的初始T细胞表面的细胞间黏附分子是否在辅助T细胞分化的初始触发中起重要作用。加入抗IL-12中和抗体不能抑制LFA-1诱导的Th1分化。这些结果表明,LFA-1介导的Th1分化不依赖IL-12。此外,我们发现慢病毒载体介导的突变(Y-F^&322>)CD226转移到初始的CD4^+辅助T细胞可以抑制CD3和LFA-1连接启动的IL-12非依赖的Th1分化。这些结果表明,CD226参与了LFA-1介导的共刺激信号,从而触发了NAVE辅助T细胞的分化。今后,我们将利用类风湿关节炎的小鼠模型,研究LFA-1/CD226介导的Th1分化与类风湿关节炎免疫病理的关系
英文摘要
Because Th1 cells are implicated in the immunopathology of rheumatoid arthritis, an understanding of molecular mechanisms of Th1fTh2 differentiation is required for development of a new therapy for rheumatoid arthritis, Th1 and Th2 cells are derived from CD4 positive naive T cells. Because CD4 positive naive T cells require intercellular binding with antigen presenting cells for differentiation of helper T cells, we investigated whether intercellular adhesion molecules on CD4 positive naive T cells may play an important role for initial triggering of differentiation of helper T cellsHere, we report that cross-linking of LFA-1 and CD3 drives Th1 differentiation from CD4 positive naive T cells from peripheral blood or cord blood cells. Addition of anti-IL-12 neutrarizing antibody did not inhibit the Th1 differentiation induced by stimulation of LFA-1. These results indicate that Th1 differentiation mediated by LFA-1 is independent on IL-12. Furthermore, we, show that lentiviral vector-mediated mutant (Y-F^<322>) CD226 transfer into naive CD4^+ helper T cells inhibited IL-12-independent Th1 differentiation initiated by CD3 and LFA-1 ligations. These results suggest that CD226 is involved in LFA-1-mediated costimulatory signals for triggering nave T helper cell differentiationIn future, we will investigate the relationship between LFA-1/CD226-mediated Th1 differentiation and the immunopathology of rheumatoid arthritis using mice with the collaoen-induced arthritis, a model for rheumatoid arthritis
期刊论文(27)
专著(0)
科研奖励(0)
会议论文
Yoh K.: "Transgenic Overexpression of GATA-3 in T Lymphocytes Improves Autoimmune Glomerulonephritis in BXSB/MpJ-Yaa Genetic Background Mice."J.Am.Soc.Nephrol.. 14. 2494-2502 (2003)
Yoh K.:“T 淋巴细胞中 GATA-3 的转基因过度表达可改善 BXSB/MpJ-Yaa 遗传背景小鼠的自身免疫性肾小球肾炎。”J.Am.Soc.Nephrol.. 14. 2494-2502 (2003)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Iwama A.: "Reciprocal roles for C/EBP and PU.I transcription factors in Langerhans cell commitment"J.Exp.Med.. 195. 547-558 (2002)
Iwama A.:“C/EBP 和 PU.I 转录因子在朗格汉斯细胞定型中的相互作用”J.Exp.Med.. 195. 547-558 (2002)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Kojima H.: "CD226 mediated platelet and megakaryocytic cell adhesion to vascular endothelial cells."J.Biol.Chem.. 278. 36748-36753 (2003)
Kojima H.:“CD226 介导血小板和巨核细胞与血管内皮细胞的粘附。”J.Biol.Chem.. 278. 36748-36753 (2003)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Shibuya K.: "CD226 (DNAM-1) is involved in LEA-1 costimulatory signal for naive T cell differentiation and proliferation."J.Exp.Med.. 198. 1829-1839 (2003)
Shibuya K.:“CD226 (DNAM-1) 参与幼稚 T 细胞分化和增殖的 LEA-1 共刺激信号。”J.Exp.Med.. 198. 1829-1839 (2003)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 10 条
    Development of the molecular targeted therapy for the chronic rejection after renal transplantation that control immunological memory
    • 批准号:
      26670575
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.33万
    • 财政年份:
      2014
    • 负责人:
      SHIBUYA Kazuko
    • 依托单位:
    Development of the molecular targeted therapy for allergic dermatitis
    • 批准号:
      25293091
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.07万
    • 财政年份:
      2013
    • 负责人:
      SHIBUYA Kazuko
    • 依托单位:
    Development of the novel molecular target therapy for the graft versus host disease (GVHD) using the humanized mice
    • 批准号:
      24659176
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.5万
    • 财政年份:
      2012
    • 负责人:
      SHIBUYA Kazuko
    • 依托单位:
    Development of a novel tumor immunotherapy that targets the soluble poliovirus receptor
    • 批准号:
      22390073
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.9万
    • 财政年份:
      2010
    • 负责人:
      SHIBUYA Kazuko
    • 依托单位:
    国内基金
    海外基金
    Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
    Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data